Aclarion (NASDAQ:ACON) Earns “Buy” Rating from Ascendiant Capital Markets

Ascendiant Capital Markets restated their buy rating on shares of Aclarion (NASDAQ:ACON) in a report issued on Monday morning, Marketbeat.com reports. The firm currently has a $1.50 price objective on the stock, down from their previous price objective of $1.60.

Aclarion Stock Down 5.2 %

Shares of NASDAQ:ACON opened at $0.22 on Monday. Aclarion has a twelve month low of $0.20 and a twelve month high of $9.90. The stock’s 50 day moving average is $0.28 and its 200-day moving average is $0.40.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The firm had revenue of $0.01 million for the quarter. Aclarion had a negative net margin of 10,246.33% and a negative return on equity of 2,554.98%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC bought a new position in Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion at the end of the most recent reporting period. 7.52% of the stock is currently owned by institutional investors and hedge funds.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.